Liver fibrosis is a major health concern worldwide. Inhibitors of Signal Transducer and Activator of Transcription 3 (STAT3) have been reported to attenuate experimental liver fibrosis. Therefore, the aim of this study was to investigate the potential ameliorative effect of cucurbitacin‐B (Cucu‐B) against CCl4‐induced liver fibrosis in mice. Treatment with Cucu‐B (5 mg/kg) preserved hepatocellular membrane integrity and amended the metabolic function as indicated by preventing the rise of serum liver function markers. This was confirmed histologically. CCl4‐induced oxidative stress was improved by Cucu‐B treatment (1 and 5 mg/kg). Furthermore, Cucu‐B treatment ameliorated the fibrotic state as evidenced by inhibiting the rise of hydroxyproline liver content and mitigating the overexpressions of collagen‐1α, α‐smooth muscle actin (α‐SMA) and transforming growth factor beta (TGF‐β) as well as the downexpression of matrix metalloproteinase‐2 (MMP‐2) mRNA. Importantly, STAT3 activity was inhibited by Cucu‐B as confirmed by decreased phosphorylation of STAT3 without changing total STAT3 expression. This was substantiated by the reduced Bcl‐2 together with increased Bax mRNA expressions with subsequent elevation of Bax/Bcl‐2 ratio. In conclusion, Cucu‐B hampers CCl4‐induced liver fibrosis in mice. This can be attributed—at least partly—to inhibition of oxidative stress, inflammation and STAT3 signalling.
Chemical Biology & Drug Design – Wiley
Published: Jan 1, 2018
Keywords: ; ; ; ;
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
All the latest content is available, no embargo periods.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud